

## **Drug Utilization Review (DUR) Meeting Minutes**

### **August 8<sup>th</sup>, 2005**

**Members Present:** Albert Samuelson, Greg Pfister, John Savageau, Patricia Churchill, Carrie Sorenson, Cheryl Huber, Leann Ness, Norma Byers, Scott Setzepfandt, Gary Betting

**Medicaid Pharmacy Department:** Brendan Joyce

**HID Staff Present:** Candace Rieth, Steve Espy

**Members Absent:** Jay Huber, Bob Treitline

Chair John Savageau called the meeting to order at 1:05pm and asked for a motion to approve the minutes from the June 6, 2005 meeting. Norman Byers moved that the minutes be approved and Albert Samuelson seconded the motion. The chair called for a voice vote to approve the minutes, which passed with no audible dissent.

#### **Budget Update:**

Brendan Joyce reported the expenditures for FY 2004 were 45,974,797. There was 2.8% increase between FY 2004 and the projected FY 2005 budget. He further explained that the Department had to maintain only a 2.5% growth to stay within the upcoming biennium budget. Previous growth projections were 11%.

#### **Review of Zanaflex:**

This is the 2<sup>nd</sup> review of Zanaflex capsules for PA implementation. Brendan Joyce distributed a handout from the manufacturer. Steve Espy explained that he spoke with a representative from Acorda and offered the opportunity for the representative to present to the Board. Instead, a handout about Zanaflex capsules was sent to Brendan. Brendan noted the difference in price between Zanaflex capsules and Tizanidine tablets was \$1.61./capsule and .55 /tablet. John Savageau explained the criteria for Prior Authorization for Zanaflex capsules. Scott Setzepfandt suggested that dysphagia be included as a criteria. John Savageau moved to accept the prior authorization form and algorithm as presented. Carrie Sorenson seconded the motion. The motion was approved by voice vote with no audible dissent.

#### **Review of Board Policy and Procedures:**

John Savageau, at the previous meeting, asked for a review of the Board Policy and Procedures. John explained to the Board the need to accelerate the decisions the Board makes. HID gave examples in the DUR pak of several states Board Policy and Procedures for the Board to review. John Savageau explained the difference between the current and the proposed Board Procedures. After much discussion, Albert Samuelson moved to accept the new procedures. Patricia Churchill seconded the motion. The motion carried by voice vote with one dissenting vote.

#### **Public Comment:**

There was public comment from Joel Gilbertson, an attorney speaking on behalf of PhRMA. Mr. Gilbertson raised concerns about the period of time the Board has to discuss recommendations as well as the language of the proposed Policy and Procedures. Brendan explained that even though the Board voted to accept the new procedures that until the Department agreed, the Board would operate under the old procedures. This topic will be brought up again at the next Board meeting for finalization. Brendan also stated that the Department will be requiring that in the future, the DUR pack will be posted on the internet 8 weeks in advance. Brendan also stated that all future meetings will be held quarterly. Representative Bill Devlin suggested that the Board stay with the current Policy and Procedures and let the legislature make the changes to the Policy and Procedures down the road.

#### **Review of Impact of Cox II inhibitors on GI Bleed:**

Steve Espy reviewed the graphs enclosed in the DUR pack. The graphs indicated that the increased utilization of Cox II inhibitors did not alter the incidence of GI bleed.

**Review of Average Daily Consumption of ADHD Agents:**

Steve Espy reviewed the table provided that reported all but one sustained release ADHD agent was being prescribed more than once daily. Steve also reviewed the graphs that depicted the utilization of immediate release and sustained release products. There was discussion concerning the increase in utilization of these agents and Cheryl Huber shared points of interest from several pediatric psychiatrists:

- ADHD is not just a school time disease
- Multiple dosing of sustained release products is necessary to prevent abrupt changes throughout the day
- Multiple dosing is necessary when patients are in after school programs and also for homework at night
- Many of the patients using multiple doses of a sustained release product also have co-morbidities
- Education should be directed at family practice rather than psychiatrists

The Board instructed HID to obtain guidelines and standards of care for use of the ADHD agents. There was public comment that followed. Dr. Byers asked if there was a way to know which prescriptions were being written by family practice doctors and which were written by specialists.

**Utilization of SROA agents:**

Steve Espy reviewed the graphs of several specific sustained release narcotics, indicating the dramatic increase in utilization of Oxycontin and Duragesic. There was much discussion on the appropriate use of these drugs and if there are ways to control utilization. Brendan Joyce asked the Board to recommend to the Department that he do a survey of the providers to find out diagnoses, directions and whether or not the doctor is using a contract on the patients taking these medications. John Savageau asked HID to produce a report that indicated the number of single prescriptions for the SROA agents.

**Summary of state actions of Oxycontin:**

Steve Espy reviewed the list of states provided and their actions on Oxycontin. Ten out of thirteen states require a prior authorization for Oxycontin.

**Summary of State actions on statins:**

Steve Espy reviewed the list of states provided and their action on the drug class statins. The majority of the states require a prior authorization on statins. The Board instructed HID to bring back, as an agenda item, utilization data, cost analysis and proposed criteria for potential prior authorization of the statin drug class.

**Review of Revatio:**

Brendan Joyce reviewed the enclosed information provided for Revatio, including the PA form and criteria. He mentioned the necessity of the prior authorization in relation to the federal mandate concerning sexual offenders. Norman Byers moved to consider the recommendation to place Revatio on PA. Greg Pfister seconded the motion; the motion was approved by voice vote with no audible dissent. Brendan Joyce reminded the Board that this would be brought back for a second consideration at the next Board meeting.

**Review of Recommended Criteria:**

Brendan Joyce advised the Board that the enclosed recommended RDUR criteria are developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These criteria will be added to the current set of criteria and will be used in future RDUR cycles. Patricia Churchill moved to approve the new criteria and Carrie Sorenson seconded the motion. The motion was approved by voice vote with no audible dissent.

Steve Espy suggested the next meeting date of 11/7/05 and also recommended to set the four quarterly meetings for 2006; 1/9, 4/10, 7/10 and 10/9. These dates can be approved at the next meeting. Acting Chair Cheryl Huber adjourned the meeting at 3:35.